UBS Group AG Sells 62,771 Shares of QuidelOrtho Corporation $QDEL

UBS Group AG lessened its holdings in shares of QuidelOrtho Corporation (NASDAQ:QDEL) by 11.6% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 476,617 shares of the company’s stock after selling 62,771 shares during the quarter. UBS Group AG owned approximately 0.70% of QuidelOrtho worth $13,612,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in the business. State of Alaska Department of Revenue raised its position in QuidelOrtho by 1.1% during the fourth quarter. State of Alaska Department of Revenue now owns 38,333 shares of the company’s stock valued at $1,093,000 after acquiring an additional 424 shares in the last quarter. Moody National Bank Trust Division raised its holdings in QuidelOrtho by 1.0% during the fourth quarter. Moody National Bank Trust Division now owns 51,512 shares of the company’s stock valued at $1,471,000 after buying an additional 526 shares in the last quarter. Nisa Investment Advisors LLC raised its holdings in QuidelOrtho by 118.1% during the third quarter. Nisa Investment Advisors LLC now owns 1,280 shares of the company’s stock valued at $38,000 after buying an additional 693 shares in the last quarter. Amalgamated Bank raised its holdings in QuidelOrtho by 3.7% during the third quarter. Amalgamated Bank now owns 19,533 shares of the company’s stock valued at $575,000 after buying an additional 695 shares in the last quarter. Finally, California State Teachers Retirement System raised its holdings in QuidelOrtho by 1.2% during the second quarter. California State Teachers Retirement System now owns 62,188 shares of the company’s stock valued at $1,792,000 after buying an additional 725 shares in the last quarter. Institutional investors own 99.00% of the company’s stock.

QuidelOrtho Trading Up 3.1%

QuidelOrtho stock opened at $11.39 on Friday. The company has a debt-to-equity ratio of 1.33, a quick ratio of 0.80 and a current ratio of 1.43. The business’s 50-day simple moving average is $14.98 and its 200-day simple moving average is $22.91. The firm has a market capitalization of $776.68 million, a PE ratio of -0.64 and a beta of 0.75. QuidelOrtho Corporation has a 52 week low of $9.92 and a 52 week high of $35.58.

QuidelOrtho (NASDAQ:QDEL) last posted its quarterly earnings data on Tuesday, May 5th. The company reported ($0.04) EPS for the quarter, missing analysts’ consensus estimates of $0.37 by ($0.41). The business had revenue of $619.80 million during the quarter, compared to the consensus estimate of $665.23 million. QuidelOrtho had a positive return on equity of 4.25% and a negative net margin of 45.57%.The company’s revenue for the quarter was down 10.5% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.74 earnings per share. QuidelOrtho has set its FY 2026 guidance at 1.800-2.000 EPS. Equities research analysts forecast that QuidelOrtho Corporation will post 1.83 earnings per share for the current year.

Wall Street Analyst Weigh In

Several equities analysts have weighed in on QDEL shares. Zacks Research lowered QuidelOrtho from a “hold” rating to a “strong sell” rating in a report on Tuesday, February 17th. Weiss Ratings restated a “sell (e+)” rating on shares of QuidelOrtho in a report on Tuesday, April 21st. Citigroup cut their target price on QuidelOrtho from $30.00 to $13.00 and set a “neutral” rating on the stock in a report on Wednesday, May 6th. Jefferies Financial Group lowered shares of QuidelOrtho from a “buy” rating to a “hold” rating and dropped their price target for the company from $35.00 to $12.50 in a research report on Thursday, May 7th. Finally, Wall Street Zen lowered shares of QuidelOrtho from a “buy” rating to a “hold” rating in a research report on Sunday, April 12th. Three equities research analysts have rated the stock with a Hold rating and three have assigned a Sell rating to the stock. According to MarketBeat, the stock currently has an average rating of “Reduce” and an average target price of $14.88.

About QuidelOrtho

QuidelOrtho is a global diagnostics company formed through the merger of Quidel Corporation and Ortho Clinical Diagnostics. The combined entity develops, manufactures and markets a broad portfolio of rapid and high-throughput diagnostic solutions across immunoassay, molecular diagnostics and transfusion medicine. Its offerings span point-of-care platforms for acute care testing as well as large-scale automated systems designed for clinical laboratories and blood banks.

The company’s product range includes rapid antigen and antibody tests for infectious diseases, molecular assays utilizing nucleic acid amplification technology, and integrated immunodiagnostic analyzers.